News

ASTRO 2024: Hypofractionation With Simultaneous Integrated Boost in Breast Cancer

ASTRO 2024: Hypofractionated vs Conventional Regional Nodal Irradiation in Treating Invasive Breast Cancer

ASCO Quality 2024: Benefits of Acupuncture in Treating Chemotherapy-Induced Peripheral Neuropathy

ASTRO 2024: Noninferiority Trial of Hypofractionated Radiation Schedules After Mastectomy

ESMO 2024: Chemotherapy-Free Immunotherapy for Immunogenic Triple-Negative Breast Cancer

ASCO Quality 2024: Can Socioeconomic Status Influence Breast Cancer Severity?

ESMO 2024: 4-Year NATALEE Outcomes Support Ribociclib-Based Therapy in Early Breast Cancer

ESMO 2024: Supplementary Biomarker Analyses of DAISY Trial of T-DXd in Metastatic Breast Cancer

ESMO 2024: Adding SBRT to Immunotherapy and Chemotherapy in High-Risk Breast Cancer

FDA Amends Mammography Quality Standards Act

ESMO 2024: Personalized, Remote Physical Activity and Quality of Life for Breast Cancer Survivors

Early, High-Risk Breast Cancer: Expanded FDA Approval for CDK4/6 Inhibitor–Based Therapy

ESMO 2024: DESTINY-Breast12 Supports T-DXd in Patients With HER2-Positive Breast Cancer and Brain Metastases

ESMO 2024: New TROP2 Antibody-Drug Conjugate Under Study in Metastatic Breast Cancer

ESMO 2024: 10-Year Trial Update on TILs and Overall Survival in Early-Stage Breast Cancer

Can Early Patient Education Help to Manage Adverse Effects From Breast Cancer Treatment?

Factors Influencing Axillary Lymph Node Metastasis in Pure Mucinous Breast Carcinoma

Can Smartphone Apps Improve Medication Adherence in Patients With Breast Cancer?

Breast Cancer Subtypes: How Do Epithelial Cells and Macrophages Interact?

Racial Disparities and Impact of COVID-19 on Clinical Outcomes in Breast Cancer

I-SPY2 Trial: Response-Predictive Subtypes of Breast Cancer

Which Has Fewer Complications: Minimal Access or Conventional Nipple-Sparing Mastectomy?

How Best to Use Radiotherapy for Early-Stage Breast Cancer: 30-Year Trial Update Offers Clues

High-Risk, Early-Stage Breast Cancer: Tailored Dose-Dense vs Standard Adjuvant Chemotherapy

Ways to Improve Breast Cancer Screening Among Women Experiencing Homelessness

With Machine Learning, Researchers Improve Potential Blood-Based Breast Cancer Test

Why Men Should Be Screened for BRCA1/2 Variants

Insomnia and Inflammation in Breast Cancer Survivors: Tai Chi and Cognitive Behavioral Therapy

Cryoablation as an Alternative to Surgery for Clinical Trial–Ineligible Patients With Breast Cancer

Chemotherapy for Breast Cancer: Link to Gut Microbiome Disruption and Cognitive Decline?

TIL-Based Computational Pathology Biomarker for Ductal Carcinoma In Situ

Genetic Testing Guidelines for Patients With Breast Cancer

Treatments and Mortality Among Female Childhood Cancer Survivors With Subsequent Breast Cancer

NATALEE Trial: Ribociclib Plus NSAI in Node-Negative Breast Cancer Subgroup

Easing the Effects of T-DXd: Electronic Symptom Tracking Tested in PRO-DUCE Trial

Potential Prognostic Cellular Biomarker Investigated for Stage I Triple-Negative Breast Cancer

Genomic Alterations and Targeted Treatment by Race in Metastatic Breast Cancer

Palbociclib-Based Therapy for HER2-Positive and PAM50 Luminal Advanced Breast Cancer

Antibody-Drug Conjugate ARX788 Under Study in HER2-Positive Breast Cancer

Breast Cancer Treatment: FDA Approves Liquid Form of Thiotepa

ASCO 2024: Targeted Triplet for Leptomeningeal Metastasis in HER2-Positive Breast Cancer

ASCO 2024: Should PI3K Inhibitor Become Part of Standard of Care for Breast Cancer Subtype?

ASCO 2024: Prognostic Value of Hormone Receptor Status and Tumor Subtypes in BRCA-Positive Breast Cancer

Advanced Breast Cancer: Is Abemaciclib Plus Endocrine Therapy of Benefit After Disease Progression?

ASCO 2024: Adjuvant Use of Avelumab in High Risk, Early-Stage Triple-Negative Breast Cancer

ASCO 2024: Phase II Survival Update of Palbociclib Plus Exemestane in Metastatic Breast Cancer

ASCO 2024: MUC1 Vaccine Plus Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

ASCO 2024: Prognostic Role of ctDNA in the monarchE Breast Cancer Trial Population

ASCO 2024: Results From EV-202 of Enfortumab Vedotin in Breast Cancer Cohorts

ASCO 2024: Taxane-Free First-Line Regimen for Advanced HER2-Positive Breast Cancer

ASCO 2024: Is Adjuvant Endocrine Therapy Necessary for ER-Low Breast Cancer?

ASCO 2024: Novel Antibody-Drug Conjugate Under Study in Advanced Triple-Negative Breast Cancer

ASCO 2024: Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

ASCO 2024: DESTINY-Breast06 Update on T-DXd vs Chemotherapy in Metastatic Breast Cancer

Use of Everolimus in Advanced ER-Positive, HER2-Negative Breast Cancer: Molecular Features Influence Prognosis

ASCO 2024: Longest Reported Follow-up of Fertility and Pregnancy Among Survivors of Breast Cancer

Final ASCENT Trial Results: Sacituzumab Govitecan vs Chemotherapy in Triple-Negative Breast Cancer

Predicting a Woman’s Likelihood of Developing Breast Cancer: Focus on Polygenic Risk Scores

Final Recommendation Statement From USPSTF on Breast Cancer Screening

Clinical Effects of Breast-Conserving Therapy for BRCA-Mutated Disease

Coping With Fibrosis in the Years After Breast-Conserving Therapy

Early-Stage Triple-Negative Breast Cancer: Race and Pathologic Complete Response to Neoadjuvant Treatment

Technology-Based Program for Asian American Breast Cancer Survivors

Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Does Presenting Stage Impact Overall Survival?

Breast Cancer Survivors and Risk for Primary Lung Cancer

Triple-Negative Breast Cancer: Aurora Kinase Inhibition and Neoadjuvant Chemotherapy

Predicting Responses to Chemotherapy-Free Neoadjuvant Therapy in Early-Stage Breast Cancer

AACR 2024: Immunostimulatory Properties of Low-Dose Chemotherapy in Triple-Negative Breast Cancer

AACR 2024: Response to Aromatase Inhibitors in ER-Positive Breast Cancer

AACR 2024: New-Generation PARP Inhibitor Under Study in HER2-Negative Breast Cancer

ASBrS 2024: How Will the Decline of Surgical Reimbursements Impact Breast Cancer Care?

AACR 2024: Novel Compounds May Target MIEN1 Pathway to Treat Breast Cancer

Retrospective Study Offers Insight Into Possible Overuse of Axillary Surgery

AACR 2024: DARPP-32 Protein and Progression of Breast Cancer

AACR 2024: Study Finds Potentially Targetable Mechanistic Pathway in Breast Cancer